Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Category: Biotech/Pharma Business
-
By James DeGiulio — Pfizer's exclusive right to sell atorvastatin, the active pharmaceutical ingredient in the blockbuster cholesterol drug Lipitor, ended yesterday, November 30, the day generic competitors are licensed to enter the market as agreed upon during settlement of past patent litigations. It was a day the pharma giant has been dreading for quite…
-
By Donald Zuhn — Last week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the third quarter of 2011. The NVCA quarterly study, which the group conducts with PriceWaterhouseCoopers using data from Thomson Reuters, indicates that venture capitalists…
-
By Donald Zuhn — Last month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the second quarter of 2011. The NVCA quarterly study, which the group conducts with PriceWaterhouseCoopers using data from Thomson Reuters, indicates that venture…
-
By Kevin E. Noonan — Steve Burrill, President and CEO of Burrill & Co. took the stage at BIO 2011 in Washington, D.C. last Tuesday, and spent his 90 minutes in a brief retrospective of his 25 years in the biotechnology industry as well as his impressions and opinions on the current state of that…
-
By Donald Zuhn — Earlier this month, the Battelle Memorial Institute announced the issuance of a report concerning the economic impact of the Human Genome Project. In the report, the research group indicated that the return on the $3.8 billion the U.S. government invested in the project between 1988 and 2003 totaled $796 billion. The…
-
By Donald Zuhn — A study released earlier this year by Ocean Tomo highlights the emergence of intellectual capital and how the U.S. has transitioned to an innovation-based economy over the past 35 years. The company's Intangible Asset Market Value study indicated that in 2010, 80% of company value (for the S&P 500) was comprised…
-
By Donald Zuhn — Last week, Dow Jones VentureSource reported that investors put $6.4 billion of venture capital into 661 deals in the first quarter of 2011, which constituted a 35% increase in funding and a 5% increase in deals as compared with the same period last year. VentureSource noted that corporations provided $448 million…
-
By Donald Zuhn — Last week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the first quarter of 2011. The NVCA quarterly study, which the group conducts with PriceWaterhouseCoopers using data from Thomson Reuters, indicates that venture…
-
By Kevin E. Noonan — In anticipation of President Obama's State of the Union address tomorrow, Jim Greenwood, President and CEO of the Biotechnology Industry Organization made a recommendation today in The Arena portion of the Politico website: The president's State of the Union should, rightly, focus on jobs, particularly the need to create and…
-
By Kevin E. Noonan — In his latest report on the biotechnology sector ("Biotech 2011 – Life Sciences: Looking Back to See Ahead"), Steve Burrill (at right), CEO of Burrill & Co. continues the theme he has advanced for the past several years, with a twist. As reported in various industry media outlets (including MedCity…
Patent Docs 